Immutep Limited American Depositary Shares

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook r...

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respect...

A class action lawsuit has been filed against Immutep Limited alleging that company defendants made materially false and misleading statements regarding the TACTI-004 trial's status and prospects. The complaint claims defendants concealed negative clinical data and misrepresented the trial's operational progress and interim futility analysis timi...

The Schall Law Firm is seeking investors to join a class action lawsuit against Immutep Limited for securities fraud. The company allegedly made false and misleading statements about its TACTI-004 trial results, claiming 'strong operational progress' while knowing the trial would fail to meet its primary efficacy endpoints. Investors who purchase...